Filed - Glenmark

Active Pharmaceutical Ingredients
Current Status
Plan going forward…
Revenue increase (28.7%) driven by:
• Growth in regulated markets
• New product introductions
Mix of revenues from segments:
• India and co-marketing – 55%
• Exports – 45%
Commenced commercial supplies of
DMFs during year; several samples,
validation, pivotal batches to global
generic players for their
ANDA/Dossier filings
Filed 6 DMFs in H1
Capacity de-bottlenecking initiated
for Ankleshwar, commenced preconstruction
work at new site
Aurangabad
Revenue growth in excess of 30%
Complete capacity expansion in
Ankleshwar, start construction in
Aurangabad
File 12-14 DMFs for the year
Commercial supplies to regulated
markets to increase dramatically with
several ANDAs/Dossiers filed and
pending from out 3rd party
customers
Develop several APIs annually to
provide cost and timing advantage to
complement our US and Europe
generic filings
Continue to be a preferred 3 rd party
API supplier to the generic industry
Expect to Meet Guidance for FY07
25